Compare
Monte Rosa Therapeutics, Inc. vs Scilex Holding Co vs Bio-Techne Corp vs Qiagen N.V.
| Latest fiscal year | Monte Rosa Therapeutics, Inc. GLUE | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) | Bio-Techne Corp TECH | Qiagen N.V. QGEN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $123.67M | $30.25M | $1.22B | $2.09B |
| Revenue growth (YoY) | +63.5% | -46.5% | -0.4% | +5.7% |
| Gross margin | n/a | 65.0% (computed) | 65.8% | 62.2% |
| Operating margin | -43.8% | n/m | 20.7% | 22.3% |
| Net margin | -31.2% | n/m | 15.0% | 20.3% |
| Net income | -$38.63M | -$374.05M | $181.86M | $424.88M |
| EPS (Diluted) | n/a | -$36.48 | $1.16 | $1.94 |
| Operating cash flow | -$22.80M | $3.82M | $292.07M | $654.33M |
| Free cash flow | -$27.50M | $3.68M | $263.22M | $453.28M |
| Cash & equivalents | $129.88M | $4.96M | $264.71M | $839.00M |
| Total assets | $448.66M | $364.98M | $2.59B | $6.28B |
| Total liabilities | $215.60M | $576.73M | n/a | n/a |
| Shareholders' equity | $233.06M | -$207.78M | $2.11B | $3.78B |
| Return on year-end equity | -16.6% | n/a | 8.6% | 11.2% |
| Shares outstanding | 65.54M | 7.03M | 156.10M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Monte Rosa Therapeutics, Inc. | Scilex Holding Co | Bio-Techne Corp | Qiagen N.V. |
|---|---|---|---|---|
| Latest | $123.67M Ended 2025-12-31 | n/a | $1.22B Ended 2026-06-30 | $2.09B Ended 2025-12-31 |
| 1 year earlier | $75.62M Ended 2024-12-31 | n/a | $1.22B Ended 2025-06-30 | $1.98B Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | n/a | $1.16B Ended 2024-06-30 | $1.97B Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $1.14B Ended 2023-06-30 | $2.14B Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $1.11B Ended 2022-06-30 | $2.25B Ended 2021-12-31 |